ISCT works with industry to launch cell therapy partnership

Biotech firms Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies are joining the International Society for Cellular Therapy (ISCT) to launch a series of initiatives to create greater strategic alignment within the industry and drive late stage clinical development.

Established in 1992, ISCT works to foster international translational research; inform national and global regulatory framework development and harmonization; drive commercialization strategies; and educate principal investigators, lab directors, technologists, regulators and commercial stakeholders, according to the society's website.

The society's industry task force, which includes these biotechs, has unveiled a series of recommendations to re-charter the ISCT Commercialization Committee to drive the creation of forums for discussion of shared concerns on process and product development, business models, and clinical development, and to catalyze the development of consensus standards.

"Working in partnership to develop standards around cell characterization and potency as well as treatment approaches and trial endpoint design we aim to facilitate entry into the cell therapy space for large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced phase clinical trials. Ultimately, this will expedite the maturation of the field and bring cell therapy treatments to patients faster," says Ed Horwitz, president of ISCT, in a statement.

- check out ISCT's release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.